Effects of vorapaxar on clot characteristics, coagulation, inflammation, and platelet and endothelial function in patients treated with mono- and dual-antiplatelet therapy

BACKGROUND: Vorapaxar is indicated with standard antiplatelet therapy (APT) in patients with a history of myocardial infarction (MI) or peripheral arterial disease (PAD). OBJECTIVES: To evaluate the comparative effects of vorapaxar on platelet-fibrin clot characteristics (PFCC), coagulation, inflamm...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:J Thromb Haemost
मुख्य लेखकों: Bliden, Kevin, Chaudhary, Rahul, Kuliopulos, Athan, Tran, Henry, Taheri, Hamid, Tehrani, Behnam, Rosenblatt, Arnold, Navarese, Eliano, Tantry, Udaya S., Gurbel, Paul A.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2019
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6940524/
https://ncbi.nlm.nih.gov/pubmed/31444884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jth.14616
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन